Objective: We sought to investigate the utility of S100A12 as a biomarker for the early diagnosis and prognostication of patients presenting with ST-segment elevation myocardial infarction (STEMI). This evidence concerns the gene S100A12 and ST Elevation Myocardial Infarction.